Riskpilot← Back to searchSign inGet full accessNewron Sweden AB
ABActiveOrg 5567030118Alpstigen 6Research and experimental development on natural sciences and engineering · NACE 7210Est. 20060 employees
Revenue 2024
SEK 0
EBITDA margin
—
-11% vs 2023
Equity ratio
98.7%
Financial strength
Net profit 2024
SEK 53K
+150% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -207K | -11% |
| Net profit | SEK 53K | +150% |
| Total assets | SEK 10,1M | +0% |
| Equity | SEK 10M | +1% |
| Employees | 0 | — |
Legal name
Newron Sweden AB
Org number
5567030118
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
28 april 2006
Share capital
SEK 3 130 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget har till syfte att utveckla läkemedel mot sjukdomar i framför allt nervsystem samt bedriva annan därmed förenlig verksamhet.
Address
Alpstigen 6
Email
ewa.forsman@newronsweden.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −195 | −201 | −198 | −186 | −207 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −195 | −201 | −198 | −186 | −207 |
| Net financials | 408 | 197 | 308 | 80 | 260 |
| Profit before tax | 300 | −5 | 109 | −105 | 53 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 300 | −5 | 109 | −105 | 53 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 10 041 | 9 997 | 10 126 | 10 063 | 10 086 |
| Equity | 9 904 | 9 899 | 10 008 | 9 903 | 9 956 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 137 | 98 | 118 | 160 | 130 |
| Total debt | 137 | 98 | 118 | 160 | 130 |
EBITDA margin
-20700000.0%
This company
15.8%
Market median
-131012758% vs market
20202024
Equity ratio
98.7%
This company
38.2%
Market median
+158% vs market
20202024
Return on equity
0.5%
This company
18.4%
Market median
-97% vs market
20202024
Net profit margin
5300000.0%
This company
8.1%
Market median
+65431999% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
EM Authorized Recipient of Service | Authorized Recipient of Service | 2020 |
PS Chief Auditor | Chief Auditor | 2022 |
| Former (1) | ||
BS Chief Auditor | Chief Auditor | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2020 | |
| Board of Directors | 2023 | |
| Chairman | 2020 | |
| Former (1) | ||
| Board of Directors | 2020 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NEWRON PHARMACEUTICALS S.P.A.
Newron Sweden AB (this company)Board members of Newron Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ewa Maria Forsman | Authorized Recipient of Service | 0 companies |
| Pontus Stefan Axel Ohlsson | Chief Auditor | 0 companies |
| Björn Sture Bernhard Peters Ohlsson | Chief Auditor | 0 companies |
| Marco Caremi | Board of Directors | 0 companies |
| Roberto Galli | Deputy Board Member | 0 companies |
| Filippo Silvio Moriggia | Board of Directors | 0 companies |
| Stefan Weber | Chairman | 0 companies |